Kenvue Inc. (KVUE)
NYSE: KVUE · Real-Time Price · USD
16.08
-0.14 (-0.86%)
At close: Oct 8, 2025, 4:00 PM EDT
16.10
+0.02 (0.12%)
After-hours: Oct 8, 2025, 5:51 PM EDT
Kenvue Employees
Kenvue had 22,000 employees as of December 29, 2024. The number of employees did not change compared to the previous year.
Employees
22,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$688,227
Profits / Employee
$64,455
Market Cap
30.86B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 22,000 | 0 | - |
| Dec 31, 2023 | 22,000 | -200 | -0.90% |
| Dec 31, 2022 | 22,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Walmart | 2,100,000 |
| PepsiCo | 319,000 |
| Costco Wholesale | 316,000 |
| Anheuser-Busch InBev | 143,885 |
| Unilever | 120,040 |
| The Procter & Gamble Company | 109,000 |
| Mondelez International | 90,000 |
| Philip Morris International | 83,100 |
KVUE News
- 5 days ago - Does Tylenol cause autism? Researchers can use ‘natural experiments' to study the link, write Drs. - WSJ
- 11 days ago - Kenvue: Trump-Era Volatility Presents A More Attractive Opportunity, But Headwinds Remain - Seeking Alpha
- 11 days ago - The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails. - WSJ
- 12 days ago - Trump repeats Tylenol and vaccine claims, defying medical community outcry - Reuters
- 12 days ago - 51 September S&P Hi-Yield Aristocrats: 5 To Buy - Seeking Alpha
- 12 days ago - RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? - Forbes
- 13 days ago - Attorneys urge court overseeing Tylenol autism lawsuits to consider Trump administration's stance - Reuters
- 13 days ago - RFK Jr.'s team wanted to tout an autism therapy. But a meeting with Tylenol's maker convinced the U.S. health secretary to put the emphasis on acetaminophen - WSJ